Citations

Clear

5 citation(s) found for "Chhablani, Jay".

DELAYED RHEGMATOGENOUS RETINAL DETACHMENT AFTER MACULAR SURGERY
Singh, Sumit Randhir , Boscia, Giacomo, Ferrara, Mariantonia , Menzio, Sara, Veritti, Daniele , Kuppermann, Baruch D., Singh, Rishi P. , Rezaei, Kourous A., Israilevich, Rachel , Chhablani, Jay, Boscia, Francesco , Boscia, Giacomo, Romano, Mario Rosario , Sarao, Valentina , Lanzetta, Paolo , Arévalo, J. Fernando , Parolini, Barbara , Hassan, T. , Wu, Lihteh , Starr, Matthew R. , Chhablani, Jay

Mayo Clinic

Retina | February 26, 2025 | Volume: 45 | Issue: 6 | Pages: 1050-1055

10.1097/iae.0000000000004433 | PMID 39999814 Get It

Purpose: To report the anatomic and visual outcomes of eyes developing delayed rhegmatogenous retinal detachment (RRD) after macular surgery. Methods: This was a retrospective, multicentric study including eyes undergoing RRD repair at least 3 months after macular surgery for either full-thickness macular hole (FTMH) or epiretinal membrane (ERM). Anatomic and functional assessment, i.e., pre- and postoperative best-corrected visual acuity (BCVA), indications and details of macular and RRD surgery, time interval from macular surgery to RRD, intraocular tamponade, location, extent of RRD, and nature of retinal break, was performed. Results: Sixteen out of 2,906 eyes (0.55%) undergoing macular surgery developed RRD after 8.4 ± 5.8 months (mean ± SD). Intraoperative peripheral retina evaluation showed missed/de novo break (11 eyes; 68.75%), no identifiable break i.e., probable microbreak (two eyes; 12.5%), giant retinal tear (two eyes; 12.5%), and retinoschisis related break (one eye; 6.25%). Anatomical success, i.e., attached retina after one surgery, was seen in 14 eyes (87.5%). BCVA worsened from 0.6 ± 0.3 logMAR (Snellen equivalent 20/80) at baseline to 0.9 ± 0.8 logMAR (20/160) through the last visit (P < 0.001). Conclusion: RRD after macular surgery occurs predominantly via missed/de novo retinal breaks. A significant percentage (50%) of eyes showed worse visual acuity compared with baseline despite successful retinal reattachment.
Ziv‐aflibercept: A cost‐effective, off‐label, highly potent antagonist of vascular endothelial growth factor
Mansour, Ahmad M. , Stewart, Michael W., Farah, Michel Eid , Mansour, Hana A. , Chhablani, Jay

Mayo Clinic

Acta Ophthalmologica | December 21, 2019 | Volume: 98 | Issue: 5 | Pages: No page available

10.1111/aos.14328 | PMID 31863550 Get It

AbstractZiv‐aflibercept (Zaltrap®), a recombinant fusion protein that binds diffusible vascular endothelial growth factor (VEGF), is approved for the treatment of metastatic colorectal carcinoma. Its molecular structure is the same as aflibercept (Eylea®), thus making it an attractive option for the off‐label treatment of chorioretinal vascular conditions. Ziv‐aflibercept is distributed in 4 and 8 ml vials for intravenous use, and its cost after compounding is similar to bevacizumab. Studies with retinal pigment epithelium cytotoxicity, animal histologic sections and electroretinography have demonstrated its safety, and mathematical modelling combined with over four dozen clinical publications from different ophthalmic centres throughout the world attest to its efficacy. No appreciable differences in visual or anatomic outcomes between 1.25 mg (0.05 ml) and 2.5 mg (1.0 ml) doses have been noted. The long duration of action combined with the low cost make ziv‐aflibercept an attractive anti‐VEGF treatment option, especially in low‐ and middle‐income countries where its popularity is increasing.
SHORT-TERM SAFETY OF 2 MG INTRAVITREAL ZIV-AFLIBERCEPT
Chhablani, Jay , Dedhia, Chintan , Peguda, Hari Kumar , Stewart, Michael, group, on behalf of Ziv-aflibercept study, group, on behalf of Ziv-aflibercept study

Mayo Clinic

Retina | January 4, 2017 | Volume: 37 | Issue: 10 | Pages: 1859-1865

10.1097/iae.0000000000001440 | PMID 28060148 Get It

Purpose: To evaluate the safety of single intravitreal 2 mg ziv-aflibercept (0.08 mL) injections for the treatment of choroidal neovascular membranes (CNVM). Methods: Eyes with choroidal neovascular membranes because of several conditions each received single intravitreal injections of 2 mg ziv-aflibercept (0.08 mL). Comprehensive ophthalmic examinations and detailed systemic evaluations were performed at baseline and Days 1, 7, and 30 after injections. Standard electroretinography was performed at baseline and Day 30. Primary outcome measures consisted of safety assessments (signs of clinical toxicity and electroretinographic abnormalities). Secondary outcome measures included changes in best-corrected visual acuity (BCVA) and central subfield thickness (CST) of the macula. Results: Twenty-one eyes of 20 patients (12 males) received injections. Etiologies responsible for the choroidal neovascular membranes included age-related macular degeneration (14), polypoidal choroidal vasculopathy (PCV) (3), myopia (2), and idiopathic juxtafoveal telangiectasia (2). None of the patients complained of worsening vision or pain after the intravitreal injections and no intraocular inflammation was seen. No significant changes in the electroretinographic b/a ratio from baseline to 1 month were measured (scotopic: P = 0.89; photopic: P = 0.13) and mean intraocular pressures were unchanged (14.2 ± 3.6 vs. 13.7 ± 3.0 mmHg; P = 0.62). Mean best-corrected visual acuity did not change significantly from baseline to 1 month (0.66 ± 0.37 logMAR [Snellen equivalent: 20/100] vs. 0.61 ± 0.35 logMAR [Snellen equivalent: 20/80]; P = 0.72) but significant improvements in central subfield thickness were seen (343 ± 177 vs. 210 ± 133 μ m; P = 0.01). Conclusion: Single intravitreal injections of 2 mg ziv-aflibercept (0.08 mL) appear to be safe through 1 month.
Clinical Characteristics and Treatment Outcomes of Recurrent Central Retinal Vein Occlusions
Chhablani, Jay , Stewart, Michael, Paulose, Remya, Gallego‐Pinazo, Roberto , Dolz‐Marco, Rosa

Mayo Clinic

Seminars in Ophthalmology | September 10, 2016 | Volume: 33 | Issue: 2 | Pages: 191-197

10.1080/08820538.2016.1188130 | PMID 27610480 Get It

FLATTENING OF A TREATMENT-RESISTANT RETINAL PIGMENT EPITHELIAL DETACHMENT AFTER A SINGLE INTRAVITREAL INJECTION OF ZIV-AFLIBERCEPT
Yogi, Rohit, Stewart, Michael, Chhablani, Jay

Mayo Clinic

RETINAL Cases & Brief Reports | April 19, 2016 | Volume: 11 | Issue: 2 | Pages: 111-113

10.1097/icb.0000000000000305 | PMID 27078613 Get It

Purpose: To report flattening of a treatment-resistant retinal pigment epithelial detachment (PED) due to neovascular age-related macular degeneration after a single intravitreal injection of ziv-aflibercept (Zaltrap). Methods: A 67-year-old woman with a neovascular age-related macular degeneration–related PED was treated with intravitreal injections of bevacizumab and ranibizumab, and in combination with verteporfin photodynamic therapy, before receiving a single intravitreal injection of ziv-aflibercept (1.25 mg/0.05 mL). Results: The patient presented with a visual acuity of 20/30 in the right eye, a PED height of 581 μm, and a central macular thickness of 381 μm. She received eight intravitreal injections of bevacizumab and ranibizumab, one in combination with photodynamic therapy. The height of the PED and the central macular thickness varied over time, but 3 years later, they measured 382 μm and 418 μm, respectively. A single intravitreal injection of ziv-aflibercept resulted in a dramatic reduction in PED height to 140 μm, which was maintained 2 months later. The visual acuity remained stable, and there were no clinical signs of toxicity. Conclusion: Intravitreal ziv-aflibercept safely and effectively improved a treatment-resistant PED. Intravitreal ziv-aflibercept could become a treatment option for neovascular age-related macular degeneration in countries where aflibercept (Eylea) is not available or its cost is prohibitive, but further studies are necessary to establish efficacy and safety.